Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shigella flexneri 2a-shigella sonnei bivalent conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- Zhifei Biological
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The shigella flexneri 2a-shigella sonnei bivalent conjugate vaccine is a bivalent conjugate vaccine designed to prevent shigellosis caused by *Shigella flexneri 2a* and *Shigella sonnei*. It consists of O-specific polysaccharides (O-SP) purified from the lipopolysaccharide (LPS) of *S. flexneri 2a* and *S. sonnei*, which are covalently bonded to tetanus toxoid (TT) as a carrier protein. This conjugation aims to enhance the immune response, particularly in young children, by inducing protective antibodies against these two prevalent *Shigella* serotypes. Developed by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd, the vaccine is currently undergoing Phase III clinical trials to evaluate its efficacy, immunogenicity, and safety in infants and children aged 6 months to 5 years. Each intramuscular dose contains 10 µg of *S. flexneri 2a* polysaccharide and 10 µg of *S. sonnei* polysaccharide.
- Other names
- S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine
Beyond the preview
Go deeper on shigella flexneri 2a-shigella sonnei bivalent conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shigella flexneri 2a-shigella sonnei bivalent conjugate vaccine.